Post by
Eoganacht on Sep 27, 2023 11:29am
Theralase chooses most deadly over most common cancer ...
...for it's next trial
There are around 300,000 GBM cases globally every year. Around 38% of those patients will be dead within a year of diagnosis. Less than 7% will survive more than 5 years.
There are over 2,000,000 NSCLC cases annually. If it is caught early 70% - 92% of these patients could still be alive at 5 years.
So ir seems Theralase has chosen the most difficult to treat, less potentially profitable cancer indication for it's next trial.
A big win with GBM will demonstrate very quickly and very clearly what X-ray activated Rutherrin can accomplish and could definitively change attitudes towards oncological pdt.
Comment by
Longholder99 on Sep 27, 2023 11:38am
Seems like the push is on. Dr Lbiati.....BTD......GBM. Dominos falling
Comment by
Oilminerdeluxe on Sep 27, 2023 11:59am
A full war chest would be nice with all this potential to exploit. They will hopefully have solved that in time for the GBM trial.
Comment by
Gooseybear on Sep 27, 2023 2:01pm
One of my best friends died from GBM a year ago. Was in great health but only lasted a year. Three years ago my wife's best friend died of the same. Excellent health. Dead in a year. Dear friends sister died a few months ago from GBM. Excellent health. This disease is incredibly dangerous and almost impossible to treat.
Comment by
DeathXray33 on Sep 27, 2023 2:12pm
My Grandfather died from Brain Cancer when my father was only 12 yrs old. It affected him greatly. I never got to meet him. I've been supporting this company for over 10 years... >1.128 million & buying more tomorrow...
Comment by
socksnblonds642 on Sep 27, 2023 2:42pm
Wow, that really puts thing into perspective. Speaks to their confidence in Ruvidar.